EORTC评分系统预测非肌层浸润性膀胱癌TURBT术后即刻吡柔比星灌注的价值
该回顾性研究纳入484例非肌层浸润性膀胱癌患者,比较TURBT术后6小时内与10天首次吡柔比星灌注的疗效,并依据EORTC量表分层。结果显示EORTC评分0分者即刻灌注组1年、5年复发率显著低于参考值,评分1~4分者即刻灌注组1年无瘤生存率显著优于对照组;延迟即刻灌注是复发的独立危险因素。
要点
- EORTC评分0分者即刻灌注后1年、5年复发率低于参考值。
- EORTC评分1~4分者即刻灌注1年无瘤生存率显著优于对照组。
- 延迟即刻灌注是术后肿瘤复发的独立危险因素。
核心结论
- EORTC量表可较准确评价TURBT后接受即刻灌注化疗患者的疗效,复发风险评分1~4分患者获益最大。
研究设计与样本
- 回顾性分析2001年5月至2012年5月行TURBT的484例非肌层浸润性膀胱尿路上皮癌患者,285例术后6小时内首次灌注为即刻灌注组,199例术后10天首次灌注为对照组。
主要发现
- EORTC复发评分0分患者中,即刻灌注组1年、5年复发率分别为5.3%和14.0%,低于EORTC参考值15.0%和31.0%(P<0.05)。
- EORTC复发评分1~4分患者中,即刻灌注组1年无瘤生存率81.3%,高于对照组76.7%(P=0.014)。
- EORTC复发评分5~9分患者中,即刻灌注组与对照组1年无瘤生存率分别为73.3%和70.2%,差异无统计学意义(P>0.05)。
- EORTC复发评分10~17分患者中,即刻灌注组与对照组1年无瘤生存率分别为50.1%和48.3%,差异无统计学意义(P>0.05)。
- 285例即刻灌注患者1年、5年进展率与EORTC参考值比较差异均无统计学意义(均P>0.05)。
关键数值与推荐
- Cox多因素分析显示既往复发史、病理分级、肿瘤数目、肿瘤直径和即刻灌注化疗情况与肿瘤复发均有关(均P<0.05)。
临床怎么用
- 可参考EORTC复发风险评分对TURBT术后患者分层,评分1~4分者行即刻灌注化疗可能获益最大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To assess value of immediate postoperative intravesical instillation of pirarubicin after transurethral resection (TURBT)of non-muscle invasive bladder cancer. Methods: 484 patients diagnosed with non-muscle-invasive bladder cancer admitted to the Second Affiliated Hospital of Kunming Medical University were divided into two groups after transurethral resection of bladder tumor. 285 patients received postoperative intravesical instillation of pirarubicin within 6 hours after the surgery, 199 patients received first instillation of pirarubicin at 10 days after the surgery, after that, all the patients received routine bladder perfusion chemotherapy. Patients who received intravesical instillation of pirarubicin within 6 hours were defined as immediate intravesical instillation group and the other patients as the control group. Based on the European Organisation for Research and Treatment of Cancer risk tables, scores of recurrence and progression of patients were calculated and then stratified into risk groups accordingly. Recurrence and progression rates of the immediate intravesical instillation group were analyzed and then compared with the corresponding reference of the risk tables. Results: The 1-year and 5-year recurrence rate of patients with EORTC table scoring 0 in the immediate intravesical instillation group were significantly lower than that of the EORTC reference group (5.3% and 14.0% vs 15.0% and 31.0%, P<0.05). 1-year recurrence free rate between the immediate intravesical instillation group and the control group in patients scoring 1-4 was significantly different (81.3% vs 76.7%, P=0.014). However, 1-year recurrence free rate of the immediate intravesical instillation group was comparable with that of the control group in patients scoring 5-9, 10-17(P>0.05), which is quite close to the EORTC reference. The probability rates of 1-year and 5-year progression of the 285 patients who received immediate intravesical instillation group did not show significant difference with the EORTC reference. On multivariate analysis, previous recurrence, tumor grade G2-3, tumor multiplicity, delay of immediate intravesical instillation were independent risk factors of recurrence(P<0.05). Conclusions: With the help of EORTC recurrence risk table stratifying the patients into different risk groups, our study showed that delay of immediate postoperative intravesical instillation of chemotherapy after TURBT was an independent risk factor of post-surgery recurrence of tumor. Moreover, patients with EORTC scoring 1-4 might obtain greatest benefits. 目的: 探讨非肌层浸润性尿路上皮癌患者行经尿道膀胱肿瘤电切术(TURBT)后即刻灌注化疗的疗效。 方法: 回顾性分析2001年5月至2012年5月间行TURBT的484例非肌层浸润性膀胱尿路上皮癌患者的临床资料,其中285例患者术后6 h内首次接受膀胱灌注化疗,199例患者术后10 d首次接受膀胱灌注化疗。术后6 h内行首次膀胱灌注化疗的患者为即刻灌注化疗组,其余患者为对照组。参考欧洲癌症研究与治疗组织(EORTC)量表对复发和进展的患者进行评分。分析接受即刻灌注化疗患者的复发率和进展率,并与EORTC量表对比。 结果: 在285例即刻灌注化疗患者中,EORTC复发评分0分组患者的1、5年复发率分别为5.3%和14.0%,低于EORTC量表参考值(分别为15.0%和31.0%),差异均有统计学意义(P<0.05)。EORTC复发评分1~4分患者中,即刻灌注组患者的1年无瘤生存率为81.3%,高于对照组(76.7%),差异有统计学意义(P=0.014);EORTC复发评分5~9分患者中,即刻灌注化疗组和对照组患者的1年无瘤生存率分别为73.3%和70.2%,差异无统计学意义(P>0.05);EORTC复发评分10~17分患者中,即刻灌注化疗组和对照组患者的1年无瘤生存率分别为50.1%和48.3%,差异无统计学意义(P>0.05)。285例接受即刻灌注化疗患者的1、5年进展率与EORTC量表参考值比较,差异均无统计学意义(均P>0.05)。Cox多因素分析显示,既往复发史、病理分级、肿瘤数目、肿瘤直径和即刻灌注化疗情况与肿瘤复发均有关(均P<0.05)。 结论: EORTC量表可较准确地评价行TURBT后接受即刻灌注化疗的非肌层浸润性膀胱尿路上皮癌患者的疗效,EORTC复发风险评分1~4分患者的收益最大。.
引用
- Ding XL, Yang DL, Yan RP, et al. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29730921. doi:10.3760/cma.j.issn.0253-3766.2018.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。